Last reviewed · How we verify
budesonide plus formoterol combination
Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles.
Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles. Used for Maintenance and control of asthma symptoms, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | budesonide plus formoterol combination |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Corticosteroid and long-acting beta2-adrenergic receptor agonist combination |
| Target | Beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide works by inhibiting the production of pro-inflammatory cytokines, which contribute to airway inflammation. Formoterol, on the other hand, stimulates the beta2-adrenergic receptors in the airway smooth muscle, leading to bronchodilation and improved lung function.
Approved indications
- Maintenance and control of asthma symptoms
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Headache
- Cough
- Oral candidiasis
- Muscle cramps
- Nausea
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
- Ventilation and Perfusion in Asthmatics (PHASE4)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (PHASE3)
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: